Raise closed, search for fresh raises on Seedstage

Littleton, CO

Developing botanical drugs for FDA approval to treat Central Nervous System disorders.

• FDA clinical progress: Lead cannabinoid drug cleared for Phase 2 trials targeting Autism.
• Pipeline diversity: Psilocybin-based drug in development for Generalized Anxiety Disorder.
• Experienced leadership: Team includes executives from Charlotte’s Web and scientists from top medical institutions.
• Unique infrastructure: Operates a DEA-registered lab with advanced extraction and analysis capabilities.
• Strategic approach: Monetization through licensing, partnerships, and vertical integration.

Ajna BioSciences is raising funds to support the development of FDA-approved botanical drugs designed to treat Central Nervous System disorders. The company is currently advancing a pipeline of plant-based therapies, including cannabinoid and psilocybin formulations, that target conditions such as Autism, Anxiety, and PTSD. With its first drug candidate cleared for Phase 2 clinical trials and another preparing for Phase 1, Ajna is working to bring natural compounds into mainstream pharmaceutical use. The leadership team includes industry veterans and medical experts from institutions such as Johns Hopkins, NYU, and Harvard, leveraging their experience to navigate regulatory pathways and clinical development.

The fundraising will help build out Ajna’s infrastructure and continue research within its DEA-registered laboratory in Colorado. The facility is equipped for end-to-end drug development using sustainable extraction methods and advanced analytical tools. Ajna aims to bridge the gap between modern clinical standards and the therapeutic potential of botanical compounds. By pursuing FDA approval, the company intends to position itself as a pioneer in regulated plant medicine, enabling broader physician adoption and potential insurance coverage for future treatments.

Company Info

Ajna BioSciences develops FDA-compliant botanical drugs using cannabinoids and psychedelics to treat central nervous system disorders.

Ajna BioSciences is a pharmaceutical company developing FDA-approved botanical drugs targeting central nervous system disorders. The company focuses on leveraging plant-based compounds such as cannabinoids and psilocybin to create therapies for conditions including Autism Spectrum Disorder, Generalized Anxiety Disorder, and PTSD. Ajna’s approach involves formulating full-spectrum botanical drugs that comply with FDA regulatory standards for safety, consistency, and efficacy. Their pipeline includes AJA001, a cannabinoid-based treatment that has received FDA clearance to begin Phase 2 trials for autism, and AJA002, a psilocybin-based candidate in preparation for Phase 1 trials addressing anxiety.

The company operates a 13,500 sq. ft. DEA Schedule 1-registered laboratory in Colorado, enabling in-house cultivation, extraction, and analytical testing of plant and fungal compounds. Ajna utilizes QTOF mass spectrometry and other advanced technologies to standardize complex botanical formulations. The leadership team includes former executives from Charlotte’s Web and researchers affiliated with NYU, Harvard, and Johns Hopkins. Their development strategy integrates intellectual property licensing, co-development partnerships, and vertical integration to support regulatory advancement and commercialization. Ajna’s work reflects a pharmaceutical framework for botanical medicine, aiming to meet unmet medical needs through science-based natural therapies.